Following these studies on the effects of DSIF in multi-repeat gene transcription, a recent study suggested a novel therapeutic approach for combating Huntington’s disease by introducing Spt5-Pol II small molecule inhibitors (SPIs), which selectively inhibit transcription of the mutant huntingtin (Htt) gene, which has extended CAG repeats, by reproducing the DSIF knockdown effects [36]. The gene discussed is HTT; the disease is Huntington disease.